Pesquisar um ensaio clínico
Outras opções de pesquisa
16 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Financiado por um membro do IRDiRC = 
; Membro de uma ERN = 
Ensaio (s) clínico (s) nacional (is)
ESPANHA
Andalucía
SEVILLA
ORZORA: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (Phase IV) - ES
Hospital Universitario Virgen Macarena
Unidad de Oncología Médica
ESPANHA
Aragón
ZARAGOZA
ORZORA: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (Phase IV) - ES
Hospital Universitario Miguel Servet
Servicio de Oncología Médica
ESPANHA
Canarias
LA CUESTA
ORZORA: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (Phase IV) - ES
Hospital Universitario de Canarias
Servicio Oncología Médica
ESPANHA
Castilla - León
BURGOS
ORZORA: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (Phase IV) - ES
Hospital Universitario de Burgos
Servicio de Oncología
ESPANHA
Cataluña
BADALONA
ORZORA: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (Phase IV) - ES
ICO Badalona - Hospital Germans Trias i Pujol
Servicio de Oncología Médica
ESPANHA
Cataluña
BARCELONA
ORZORA: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (Phase IV) - ES
Hospital de la Santa Creu i Sant Pau
Servicio de Oncología Médica y Unidad de curas paliativas
ESPANHA
Cataluña
L'HOSPITALET DE LLOBREGAT
ORZORA: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (Phase IV) - ES
ICO Hospitalet - Hospital Duran i Reynals
Servicio de Oncología Médica
ESPANHA
Comunidad Valenciana
VALENCIA
ORZORA: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (Phase IV) - ES
Hospital Clínico Universitario de Valencia
Servicio de Oncología
ESPANHA
Comunidad Valenciana
VALENCIA
ORZORA: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (Phase IV) - ES
Hospital Universitario y Politécnico La Fe
Unidad de Hemostasia y Trombosis
ESPANHA
Madrid
MADRID
ORZORA: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (Phase IV) - ES
Hospital Clínico San Carlos
Servicio de Oncología Médica
ESPANHA
Madrid
MADRID
ORZORA: An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy (Phase IV) - ES
Hospital Universitario 12 de Octubre
Servicio de Oncología Médica
ALEMANHA
Berlin
ADDRESS: NOT PROVIDED - DE
Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial
Institution: Information not provided - DE
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors (Phase 2) - AT
Institution: Information not provided - AT
ITALIA
EMILIA ROMAGNA
BOLOGNA
A randomized, phase III trial of Patupilone vs Pegylated Liposomal Doxorubicin in Taxane in patients with recurrent epithelial ovarian, primary fallopian or primary peritoneal cancer
Policlinico S. Orsola-Malpighi - Area S. Orsola
S.S.D. Oncologia Medica
REINO UNIDO
Greater London
LONDON
A Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimens - UK
UCLH Gynaecological Cancer Centre, University College London
UCLH Gynaecological Cancer Centre, Women's Health Office Wing, 2nd Floor, North Wing
BELGICA
ARRONDISSEMENT BRUSSELS-CAPITAL
BRUSSELS